Use of big data for drug development and for public and personal health and care.
Genet Epidemiol
; 41(1): 51-60, 2017 Jan.
Article
em En
| MEDLINE
| ID: mdl-27873357
ABSTRACT
The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Saúde Pública
/
Tomada de Decisões
/
Atenção à Saúde
/
Descoberta de Drogas
/
Medicina de Precisão
/
Conjuntos de Dados como Assunto
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article